Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB versus NALFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB versus NALFON.
IBU-TAB vs NALFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)